JP6825181B2 - 膵炎を治療するための薬剤の製造におけるｉｌ−２２二量体の使用 - Google Patents

膵炎を治療するための薬剤の製造におけるｉｌ−２２二量体の使用 Download PDF

Info

Publication number
JP6825181B2
JP6825181B2 JP2016550931A JP2016550931A JP6825181B2 JP 6825181 B2 JP6825181 B2 JP 6825181B2 JP 2016550931 A JP2016550931 A JP 2016550931A JP 2016550931 A JP2016550931 A JP 2016550931A JP 6825181 B2 JP6825181 B2 JP 6825181B2
Authority
JP
Japan
Prior art keywords
dimer
pancreatitis
domain
medicament according
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016550931A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016536357A (ja
JP2016536357A5 (enExample
Inventor
シアオチアン イェン，
シアオチアン イェン，
チョン ホアン，
チョン ホアン，
トントン ウー，
トントン ウー，
カイヤン タン，
カイヤン タン，
ユイリャン ホアン，
ユイリャン ホアン，
Original Assignee
エバイブ バイオテクノロジー （シャンハイ） リミテッド
エバイブ バイオテクノロジー （シャンハイ） リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エバイブ バイオテクノロジー （シャンハイ） リミテッド, エバイブ バイオテクノロジー （シャンハイ） リミテッド filed Critical エバイブ バイオテクノロジー （シャンハイ） リミテッド
Publication of JP2016536357A publication Critical patent/JP2016536357A/ja
Publication of JP2016536357A5 publication Critical patent/JP2016536357A5/ja
Application granted granted Critical
Publication of JP6825181B2 publication Critical patent/JP6825181B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2016550931A 2013-11-07 2014-11-06 膵炎を治療するための薬剤の製造におけるｉｌ−２２二量体の使用 Active JP6825181B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201310549648.X 2013-11-07
CN201310549648.XA CN104623639A (zh) 2013-11-07 2013-11-07 白介素22二聚体在制备治疗胰腺炎药物中的应用
PCT/CN2014/090519 WO2015067198A1 (en) 2013-11-07 2014-11-06 Use of il-22 dimers in manufacture of medicaments for treating pancreatitis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019129934A Division JP2019206548A (ja) 2013-11-07 2019-07-12 膵炎を治療するための薬剤の製造におけるｉｌ−２２二量体の使用

Publications (3)

Publication Number Publication Date
JP2016536357A JP2016536357A (ja) 2016-11-24
JP2016536357A5 JP2016536357A5 (enExample) 2017-12-14
JP6825181B2 true JP6825181B2 (ja) 2021-02-03

Family

ID=53040916

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016550931A Active JP6825181B2 (ja) 2013-11-07 2014-11-06 膵炎を治療するための薬剤の製造におけるｉｌ−２２二量体の使用
JP2019129934A Pending JP2019206548A (ja) 2013-11-07 2019-07-12 膵炎を治療するための薬剤の製造におけるｉｌ−２２二量体の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019129934A Pending JP2019206548A (ja) 2013-11-07 2019-07-12 膵炎を治療するための薬剤の製造におけるｉｌ−２２二量体の使用

Country Status (8)

Country Link
US (1) US20160271221A1 (enExample)
EP (1) EP3065765B1 (enExample)
JP (2) JP6825181B2 (enExample)
CN (2) CN104623639A (enExample)
AU (1) AU2014346051B2 (enExample)
CA (1) CA2929637C (enExample)
ES (1) ES2794082T3 (enExample)
WO (1) WO2015067198A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
CN106146668A (zh) * 2015-04-01 2016-11-23 中国人民解放军第二军医大学 长效白细胞介素22的制备方法及其用途
WO2016201007A1 (en) * 2015-06-08 2016-12-15 New York University Stabilized minimal coiled-coil mimetics
MX2018000687A (es) * 2015-07-16 2018-08-01 Philogen Spa Inmunoconjugados de il22.
ES2930351T3 (es) 2016-04-15 2022-12-09 Evive Biotechnology Shanghai Ltd Un dímero de IL-22 para su uso en el tratamiento de enterocolitis necrosante
CN113056286B (zh) 2018-09-10 2025-04-29 冷泉港实验室 用于治疗胰腺炎的方法
CN110302363B (zh) * 2019-07-04 2020-10-09 北京大学第三医院（北京大学第三临床医学院） Il-22作为制备治疗pcos药物的应用及药物制剂
EP4106794A4 (en) * 2020-02-19 2024-03-20 Evive Biotechnology (Shanghai) Ltd METHOD FOR TREATING TRANSPLANT AND HOST DISEASE

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1013270A3 (en) 1992-12-02 2001-03-28 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
WO1996007399A1 (en) 1994-09-09 1996-03-14 Takeda Chemical Industries, Ltd. Sustained release preparation containing metal salt of a peptide
EP0831787B1 (en) 1995-06-07 2001-08-22 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of human growth hormone
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US6274710B1 (en) 1998-10-26 2001-08-14 Ludwig Institute For Cancer Research Antibodies which specifically bind T Cell inducible factors (TIFs)
US7597876B2 (en) * 2007-01-11 2009-10-06 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
CN100515491C (zh) * 2005-01-04 2009-07-22 健能隆医药技术（上海）有限公司 白介素-22的医药用途
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
US8690554B2 (en) * 2011-07-15 2014-04-08 Xylem Ip Holdings Llc Diaphragm pump using duckbill and other types of valves
CA2903587C (en) * 2013-03-15 2021-09-28 Genentech, Inc. Il-22 polypeptides and il-22 fc fusion proteins and methods of use

Also Published As

Publication number Publication date
CN104623639A (zh) 2015-05-20
CA2929637C (en) 2025-02-11
CA2929637A1 (en) 2015-05-14
HK1223556A1 (zh) 2017-08-04
JP2019206548A (ja) 2019-12-05
JP2016536357A (ja) 2016-11-24
EP3065765B1 (en) 2020-04-08
CN105705160A (zh) 2016-06-22
AU2014346051B2 (en) 2020-02-27
EP3065765A4 (en) 2017-08-02
EP3065765A1 (en) 2016-09-14
AU2014346051A1 (en) 2016-05-26
CN105705160B (zh) 2020-02-07
US20160271221A1 (en) 2016-09-22
WO2015067198A1 (en) 2015-05-14
ES2794082T3 (es) 2020-11-17

Similar Documents

Publication Publication Date Title
JP6825181B2 (ja) 膵炎を治療するための薬剤の製造におけるｉｌ−２２二量体の使用
JP7752152B2 (ja) 手術前、手術中または手術後に投与するためのｇｌｐ－２類似体及びｇｌｐ－２ペプチボディ
EP3065763B1 (en) Use of il-22 dimer in manufacture of a medicament for intravenous administration
CN106573072A (zh) 降低血清胆固醇的方法
JP2022547051A (ja) 治療用融合タンパク質
EP3442562B1 (en) An il-22 dimer for use in treating necrotizing enterocolitis
WO2015138638A1 (en) Long acting trail receptor agonists for treatment of autoimmune diseases
US9617325B2 (en) Treatment of IgE-mediated disease
HK1223556B (zh) Il-22二聚体在制备用於治疗胰腺炎的药物中的用途
WO2025043075A1 (en) Methods of treating myocardial infarction, ischemia, and ischemia reperfusion injury
CN113527505A (zh) 一种多肽和包含该多肽的药物组合物以及它们的应用
HK40037000A (en) Glp-2 analogs and peptibodies for administration before during, or after surgery
HK40002973B (en) An il-22 dimer for use in treating necrotizing enterocolitis
HK40002973A (en) An il-22 dimer for use in treating necrotizing enterocolitis
HK1236439A1 (en) Methods of lowering serum cholesterol
HK1227723B (en) Use of il-22 dimer in manufacture of a medicament for intravenous administration
HK1227723A1 (en) Use of il-22 dimer in manufacture of a medicament for intravenous administration

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171102

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180718

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181022

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190312

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20190712

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20190730

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20190730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190829

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200414

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20200623

C28A Non-patent document cited

Free format text: JAPANESE INTERMEDIATE CODE: C2838

Effective date: 20200623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200923

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20201006

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20201027

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20201201

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20201201

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201221

R150 Certificate of patent or registration of utility model

Ref document number: 6825181

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250